# Tetraphase Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tetraphase-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.tphase.com
- Total disclosed funding: $70M
- Latest round: Series C (May 14, 2010)
- Investors on record: 6

## About

Tetraphase Pharmaceuticals, Inc., based in the US, is a biopharmaceutical company focused on developing innovative antibiotic therapies to combat resistant infections and other serious diseases.Tetraphase Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts, US. The company specializes in antibiotic research and has undergone various strategic initiatives, including a notable IPO in March 2013, where it raised USD 75 mn by pricing 10.7 million shares at USD 7.00 each. This round was led by La Jolla Pharmaceutical Company. The firm has completed a total of 7 deals and was the target of acquisition discussions by AcelRx Pharmaceuticals, Inc. in May 2020 for USD 44.50 mn. The company was established by Paul Howard, who has a history of founding other ventures in the biopharmaceutical space.Tetraphase Pharmaceuticals, Inc. offers a range of products focused on developing novel antibiotics designed to meet the challenges of antibiotic resistance. Their product pipeline primarily targets serious bacterial infections, and they cater to both healthcare providers and institutions, ensuring that therapeutic options are available for critical care scenarios. The company operates in North America, Europe, and select regions in Asia, enhancing its capacity to respond to diverse healthcare needs across different markets.In the year 2019, Tetraphase Pharmaceuticals reported a revenue of USD 7.376 mn, while the EBITDA for the same year was USD -66.899 mn, indicating the financial dynamics of their operational structure and investments in research and development.Looking ahead, Tetraphase Pharmaceuticals plans to leverage the recent funding to accelerate the development of new antibiotic therapies targeting drug-resistant infections. The company aims to expand its market presence in Europe and Asia by 2025, enhancing distribution capabilities and collaborations with healthcare providers. The funding from the March 2013 IPO will support these strategic initiatives, including research and development for upcoming product launches, which are expected to address critical needs in the pharmaceutical market.

## Funding rounds

- Series C, May 14, 2010, $45M — Flagship Pioneering, Mediphase Venture Partners, Skyline Ventures, Presidio Partners, F-Prime Capital, Excel Venture Management
- Series B, Oct 6, 2009, $10M — Flagship Pioneering, Mediphase Venture Partners, Skyline Ventures, Presidio Partners, F-Prime Capital
- Series A, Aug 6, 2008, $15M — Flagship Pioneering, Mediphase Venture Partners, Skyline Ventures, Presidio Partners, F-Prime Capital

## Investors

- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series A, Series B, Series C
- Mediphase Venture Partners (https://capitalatlas.ai/funds/mediphase-venture-partners) — Series A, Series B, Series C
- Skyline Ventures (https://capitalatlas.ai/funds/skyline-ventures) — Series A, Series B, Series C
- Presidio Partners (https://capitalatlas.ai/funds/presidio-partners) — Series A, Series B, Series C
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A, Series B, Series C
- Excel Venture Management (https://capitalatlas.ai/funds/excel-venture-management) — Series C